Top broker names 3 ASX All Ords stocks with between 30% and 77% upside

These 3 stocks offer compelling potential upside.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This week, a top broker named 3 ASX All Ords stocks that could deliver significant upside. 

The S&P/ASX All Ords Index (ASX: XAO) has rallied 15% since its April low. 

There have been a few standout performers. For example, Pro Medicus Ltd (ASX: PME) has surged 57% since 7 April, while Lovisa Holdings Ltd (ASX: LOV) is up 40% over the same timeframe. 

Those who recently invested in the US have enjoyed even greater returns. Since 7 April, the S&P 500 Index (SP: .INX) has risen 19%, with several high-profile companies, such as Nvidia Corp (NASDAQ: NVDA) and Tesla Inc (NASDAQ: TSLA), up more than 50% from their recent low.

As a result, investors may think they've missed out on buying companies with significant upside. However, not all is lost. Broker Macquarie has named 3 ASX All Ords companies which could deliver returns between 30% and 77% from here.

Australian shares have increased at an average compound annual growth rate (CAGR) of 9.1% over the past 30 years, according to Vanguard. Therefore, this would be an excellent outcome.

two women celebrating good news on phone

Image source: Getty Images

Monash IVF Group Ltd (ASX: MVF)

The first ASX All Ords company is Monash IVF, which operates 13 permanent clinics across Australia. The company is down 40% for the year to date. Last month, it was heavily sold off due to an incident involving one of its clinics accidentally implanting another woman's embryos into a patient. This debacle attracted significant media attention, which continues to weigh on investor sentiment. 

However, Macquarie believes the ASX All Ords stock has been oversold. In a note released this week, Macquarie suggested the company is well placed to benefit from several structural tailwinds. This includes "an increase in average age of new mothers, increased male infertility, increased success rates, and increased use of donor services". 

Macquarie has a price target of $1.30 on the company, suggesting a 77% upside from the time of writing.

Vault Minerals Ltd (ASX: VAU)

Vault Minerals is a second stock named with significant upside. In stark contrast to Monash IVF, Vault Minerals has had an outstanding start to 2025, rising 34% for the year to date. 

Broker Macquarie tips Vault Minerals shares to continue rising over the next 12 months. In a recent note, the broker cited Vault Minerals' 28 May market announcement regarding its 'King of the Hills' open pit in Western Australia. Pleasingly, the company revealed that the mine has higher reserves and a longer operational life. 

The broker has placed a $0.57 price target on the ASX All Ords mining stock. This suggests 30% upside at the time of writing.

Integral Diagnostics Ltd (ASX: IDX)

Integral Diagnostics is the third company named with significant potential upside. The company provides diagnostic imaging services to general practitioners, medical specialists, and allied professionals. 

The ASX All Ords healthcare company has also been heavily sold off this year, declining 17% for the year to date. Its share price tumbled 30% in February on its half-year result, but it has rebounded 14% since then. 

Macquarie is tipping that better days lie ahead, with a price target of $3.20. The broker expects the ASX All Ords company to "benefit from cost synergies related to the CAJ merger, leading to significant EPS accretion." This price target suggests 30% upside from here at the time of writing.

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa, Macquarie Group, Nvidia, and Tesla. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Integral Diagnostics, Lovisa, Nvidia, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man pointing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Top broker predicts 200% return for which ASX share?

Big things could be coming from this small cap according to Bell Potter.

Read more »

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

Macquarie shares: Buy, hold or sell?

Two top analysts offer their outlook for Macquarie’s outperforming shares.

Read more »

A steel worker peers out from under his protective headwear which is tipped back on his head as he stares solemnly straight ahead with steel production equipment in the background.
Broker Notes

Bell Potter says this beaten-down ASX materials stock can rise 56%

Down 17% this year, Bell Potter says ASX materials stock has significant upside.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Broker Notes

This ASX small-cap is tipped to almost double in the next year

Bell Potter just raised its guidance on this ASX small-cap.

Read more »

Man sits smiling at a computer showing graphs.
Broker Notes

6 ASX 200 shares with strengthened buy ratings this week

Brokers have maintained confidence in these ASX 200 stocks amid today's volatile market conditions.

Read more »

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Morgans says hold BHP shares and buy this ASX 200 stock      

Let's see what the broker is saying about these stocks this week.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

3 ASX 200 shares just upgraded to strong buy — here's what the brokers are saying

Do any of these ASX 200 stocks appeal to you?

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »